FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Drug Claims

The U.S. Food and Drug Administration (FDA) has taken regulatory action against 30 telehealth companies for disseminating false and misleading information regarding compounded versions of GLP-1 receptor agonist drugs. These drugs, which include semaglutide and liraglutide, are approved for weight management and type 2 diabetes. The warning letters specifically cite violations where the companies' websites and promotional materials made claims that improperly suggested their compounded products were equivalent to, or the same as, the FDA-approved brand-name drugs (e.g., Ozempic, Wegovy, Saxenda). The FDA emphasizes that compounded drugs are not FDA-approved, and their safety, quality, and effectiveness have not been evaluated by the agency. The letters demand the companies immediately cease making such claims and correct the violations. This action highlights ongoing concerns about the safety and marketing of compounded medications, particularly in the rapidly growing telehealth and weight-loss drug sectors, where demand often outstrips supply of the approved products.